## Francesco Pezzella

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7901785/publications.pdf

Version: 2024-02-01

74 papers 6,234 citations

32 h-index 70 g-index

75 all docs

75 does citations

75 times ranked 9207 citing authors

#	Article	IF	CITATIONS
1	Detection of elevated levels of tumourâ€associated microRNAs in serum of patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2008, 141, 672-675.	2.5	1,570
2	bcl-2 Protein in Non-Small-Cell Lung Carcinoma. New England Journal of Medicine, 1993, 329, 690-694.	27.0	652
3	bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. British Journal of Cancer, 1994, 69, 135-139.	6.4	301
4	Vessel co-option in cancer. Nature Reviews Clinical Oncology, 2019, 16, 469-493.	27.6	285
5	Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	7.0	269
6	Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clinical Cancer Research, 2002, 8, 2595-604.	7.0	237
7	Vessel coâ€option in primary human tumors and metastases: an obstacle to effective antiâ€angiogenic treatment?. Cancer Medicine, 2013, 2, 427-436.	2.8	231
8	Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer. Cancer Research, 2002, 62, 1326-9.	0.9	156
9	Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. Journal of Cellular and Molecular Medicine, 2009, 13, 1248-1260.	3.6	154
10	Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Research, 2005, $15$ , $430-438$ .	12.0	153
11	HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6532-6537.	7.1	141
12	Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2016, 17, 1543-1557.	10.7	129
13	Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis. Cancer Cell, 2009, 15, 57-66.	16.8	120
14	Non-angiogenic tumours and their influence on cancer biology. Nature Reviews Cancer, 2018, 18, 323-336.	28.4	113
15	The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction. British Journal of Haematology, 1990, 76, 58-64.	2.5	109
16	Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax, 2007, 62, 43-50.	5.6	98
17	Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. Clinical Cancer Research, 2008, 14, 6634-6639.	7.0	84
18	Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Molecular Cancer Research, 2003, 1, 826-35.	3.4	84

#	Article	IF	Citations
19	Flow cytometric detection of the mitochondrial BCL-2 protein in normal and neoplastic human lymphoid cells. Cytometry, 1992, 13, 502-509.	1.8	83
20	Gene expression signature for angiogenic and nonangiogenic non-small-cell lung cancer. Oncogene, 2005, 24, 1212-1219.	5.9	83
21	BNIP3 as a Progression Marker in Primary Human Breast Cancer; Opposing Functions in In situ Versus Invasive Cancer. Clinical Cancer Research, 2007, 13, 467-474.	7.0	81
22	Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data. Lancet Oncology, The, 2007, 8, 488-499.	10.7	68
23	The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers, 2021, 13, 3433.	3.7	67
24	Lung Cancers Detected by Screening with Spiral Computed Tomography Have a Malignant Phenotype when Analyzed by cDNA Microarray. Clinical Cancer Research, 2004, 10, 6023-6028.	7.0	64
25	TRAP1 Regulates Proliferation, Mitochondrial Function, and Has Prognostic Significance in NSCLC. Molecular Cancer Research, 2014, 12, 660-669.	3.4	59
26	Atrial fibrillation is associated with cardiac hypoxia. Cardiovascular Pathology, 2010, 19, 102-111.	1.6	57
27	CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC. Carcinogenesis, 2012, 33, 1717-1725.	2.8	54
28	Tumor necrosis factor receptor-associated protein 1(TRAP1) regulates genes involved in cell cycle and metastases. Cancer Letters, 2010, 296, 194-205.	7.2	46
29	An Immunocytochemical Study of p53 and <i>bcl</i> -2 Protein Expression in Hodgkin's Disease. American Journal of Clinical Pathology, 1993, 99, 663-667.	0.7	44
30	Overview on the Different Patterns of Tumor Vascularization. Cells, 2021, 10, 639.	4.1	40
31	Different Growth Patterns of Non-Small Cell Lung Cancer Represent Distinct Biologic Subtypes. Annals of Thoracic Surgery, 2008, 85, 395-405.	1.3	37
32	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	6.4	37
33	Hypoxia and Myocardial Remodeling in Human Cardiac Allografts: A Time-course Study. Journal of Heart and Lung Transplantation, 2009, 28, 1119-1126.	0.6	36
34	Proline-Hydroxylated Hypoxia-Inducible Factor $1\hat{l}_{\pm}$ (HIF- $1\hat{l}_{\pm}$ ) Upregulation in Human Tumours. PLoS ONE, 2014, 9, e88955.	2.5	36
35	Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Research, 2006, 16, 93-98.	12.0	34
36	<i><math>\label{eq:signal_signal_signal}</math> <i><math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal}</math>   <math>\label{eq:signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal}</math>   <math>\label{eq:signal_signal_signal}</math>   <math>eq:signal_sig</math></i></i>	6.9	31

#	Article	IF	Citations
37	Phosphorylated VEGFR2/KDR receptors are widely expressed in Bâ€cell nonâ€Hodgkin's lymphomas and correlate with hypoxia inducible factor activation. Hematological Oncology, 2008, 26, 219-224.	1.7	30
38	Vascular coâ€option and vasculogenic mimicry mediate resistance to antiangiogenic strategies. Cancer Reports, 2022, 5, e1318.	1.4	24
39	Somatic genetic changes accompanying lung tumor development. Genes Chromosomes and Cancer, 2005, 44, 65-75.	2.8	23
40	Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Letters, 2008, 262, 87-93.	7.2	22
41	Association between hypoxic volume and underlying hypoxia-induced gene expression in oropharyngeal squamous cell carcinoma. British Journal of Cancer, 2017, 116, 1057-1064.	6.4	20
42	Next-Generation Sequencing Analysis Reveals Differential Expression Profiles of MiRNA-mRNA Target Pairs in KSHV-Infected Cells. PLoS ONE, 2015, 10, e0126439.	2.5	19
43	Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia and Lymphoma, 2008, 49, 2181-2186.	1.3	18
44	Nonâ€angiogenic tumours unveil a new chapter in cancer biology. Journal of Pathology, 2015, 235, 381-383.	4.5	17
45	Nuclear and membrane expression of the angiogenesis regulator deltaâ€like ligand 4 (DLL4) in normal and malignant human tissues. Histopathology, 2009, 54, 598-606.	2.9	16
46	Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. Journal of Thoracic Disease, 2012, 4, 212-3.	1.4	16
47	Why some tumours trigger neovascularisation and others don't: the story thus far. Chinese Journal of Cancer, 2016, 35, 18.	4.9	15
48	Immunohistological recognition of cyclin D1 expression by non-lymphoid cells among lymphoid neoplastic cells. Apmis, 2014, 122, 183-191.	2.0	14
49	The Role of JMY in p53 Regulation. Cancers, 2018, 10, 173.	3.7	14
50	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. Hematology/ Oncology and Stem Cell Therapy, 2013, 6, 20-25.	0.9	13
51	The Landscape of the Heritable Cancer Genome. Cancer Research, 2021, 81, 2588-2599.	0.9	13
52	JMY protein, a regulator of P53 and cytoplasmic actin filaments, is expressed in normal and neoplastic tissues. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 715-722.	2.8	12
53	Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes. Journal of the National Cancer Institute, 2016, 108, djw032.	6.3	11
54	Dissecting the heritable risk of breast cancer: From statistical methods to susceptibility genes. Seminars in Cancer Biology, 2021, 72, 175-184.	9.6	10

#	Article	IF	CITATIONS
55	Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma. Frontiers in Oncology, 2022, 12, 874554.	2.8	10
56	Gene Signatures Stratify Computed Tomography Screening Detected Lung Cancer in High-Risk Populations. EBioMedicine, 2015, 2, 831-840.	6.1	7
57	Twenty years after: the beautiful hypothesis and the ugly facts. Chinese Journal of Cancer, 2016, 35, 22.	4.9	7
58	Vessel co-option and angiotropic extravascular migratory metastasis: a continuum of tumour growth and spread?. British Journal of Cancer, 2022, 126, 973-980.	6.4	7
59	NUB1 and FAT10 Proteins as Potential Novel Biomarkers in Cancer: A Translational Perspective. Cells, 2021, 10, 2176.	4.1	5
60	On coalescent angiogenesis and the remarkable flexibility of blood vessels. Angiogenesis, 2022, 25, 1-3.	7.2	5
61	When Cancer Co-opts the Vasculature. New England Journal of Medicine, 2014, 370, 2146-2147.	27.0	4
62	Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis. HemaSphere, 2020, 4, e356.	2.7	4
63	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 7967-78.	0.5	4
64	HBV and HIV expression in lymph nodes of HIV positive LAS patients: histology and in situ hybridization. Molecular and Cellular Probes, 1989, 3, 125-132.	2.1	3
65	Early squamous cell lung carcinoma: prognostic biomarkers for the many. Thorax, 2019, 74, 527-528.	5.6	3
66	Inhibition of NEDD8 and FAT10 ligase activities through the degrading enzyme NEDD8 ultimate buster 1: A potential anticancer approach. Oncology Letters, 2016, 12, 4287-4296.	1.8	2
67	Pharmacogenetics implementation in the clinics: information and guidelines for germline variants., 2019, 2, 595-607.		2
68	Exosomes: recruits for tumour surveillance?. Journal of Thoracic Disease, 2017, 9, 4295-4299.	1.4	1
69	Nonangiogenic tumor growth. , 2020, , 15-32.		1
70	Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201. PLoS ONE, 2021, 16, e0249967.	2.5	1
71	The diverse lives of TRAP1. Oncoscience, 2014, 1, 560-561.	2.2	1
72	128â€Genomic insights of ecg strain patten in aortic stenosis: t wave inversion and st-segment depression are underlined by different molecular pathways. Heart, 2017, 103, A97.1-A97.	2.9	0

#	Article	IF	CITATIONS
73	130â€The convergence and divergence of molecular pathways in lv hypertrophy defined by ecg voltage versus lv mass in patients with aortic stenosis. Heart, 2017, 103, A98.1-A98.	2.9	0
74	Tumors and Blood Vessel Interactions: A Changing Hallmark of Cancer., 2017,, 504-504.		0